To access this element change to forms mode OFF
Grant Award View - GA217030
Enhancing venetoclax and other pro-apoptotic agents to improve outcomes...
GA ID:
GA217030
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
17-Oct-2021
Publish Date:
7-Feb-2022
Category:
Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2025
Value (AUD):
$149,767.02
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Postgraduate Scholarships
Grant Activity:
Enhancing venetoclax and other pro-apoptotic agents to improve outcomes for patients with haematological malignancies
Purpose:
Blood cancers kill >4,500 Australians per year. A new drug, venetoclax, has significantly improved outcomes for these patients, but relapses frequently occur. This PhD will analyse cancer cells at the single cell level to identify and specifically target the resistant populations that cause relapse. We will study how to undermine the energy metabolism of cancer cells, which may synergise with venetoclax. These projects strive to develop new treatments to improve patient care and achieve cures.
GO ID:
GO Title:
2021 NHMRC Postgraduate Scholarship scheme
Internal Reference ID:
2021/GNT2014215
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA